<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431364</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-335-701</org_study_id>
    <nct_id>NCT02431364</nct_id>
  </id_info>
  <brief_title>Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate
      the safety and tolerability of verdinexor. Verdinexor or placebo will be given on days 1 and
      3 to healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate
      the safety and tolerability of verdinexor. Verdinexor or placebo will be given on days 1 and
      3 to healthy adult subjects.

      Cohorts of 8 subjects each (6 active, 2 placebo) will be sequentially administered verdinexor
      or placebo (one dose on Day 1 and one dose on Day 3) using a dose-escalation scheme. A
      conservative, sequential, dose-escalation strategy employing decreasing escalation increments
      will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability measured by incidence of adverse events</measure>
    <time_frame>46 days</time_frame>
    <description>Safety and tolerability will be evaluated through treatment emergent adverse events (TEAEs), physical examinations, vital signs, electrocardiograms (ECGs), supportive care medications, and changes in laboratory parameters (chemistry, hematology, and urinalysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>46 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose (MTD) Determination</measure>
    <time_frame>46 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to 24 hours post-dose (AUC(0-24)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg verdinexor on Days 1 and 3 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg verdinexor on Days 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg verdinexor on Days 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg verdinexor on Days 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg verdinexor on Days 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg verdinexor on Days 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg verdinexor on Days 1 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verdinexor</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <other_name>KPT-335</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be in good health as determined by the investigator, based on the
             medical history, ECG, physical examination, and safety laboratory tests at screening.

          -  Subjects must be identified as a non-smoker at the screening visit (a non-smoker is
             defined as an individual who has abstained from smoking for at least 1 year prior to
             the screening visit and who has a â‰¤ 15 pack year history of lifetime cigarette use). A
             urine cotinine test will be performed at screening and at the time of clinic check-in
             prior to study drug treatment.

        Exclusion Criteria:

          -  The subject has any surgical or medical condition that potentially may alter the
             absorption, metabolism, or excretion of the study drug such as gastrectomy, Crohn's
             disease, or liver disease.

          -  The subject has a history of clinically significant allergies. Hay fever is allowed
             unless it is active or has required treatment within the previous 2 months.

          -  Presence of a chronic condition(s) with clinical or historical evidence of recent
             exacerbation, or other information to suggest non-control of such condition(s).

          -  History of alcohol abuse or drug addiction within 12 months of the screening visit.

          -  Any subject with active cataracts or medical history of cataracts.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Lickliter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KPT-335</keyword>
  <keyword>Verdinexor</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>First-in-Human</keyword>
  <keyword>Adult Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

